MEEK FLIP x CLO BRIDGE · EOSE IP

MEEK FLIP x CLO LEGAL BRIDGE · DAY 84 · 2026-04-28 · EOSE LABS INC.

THE STOCKS THAT VALIDATE THE IP · THE IP THAT PROTECTS THE THESIS

MEFINE TRADING POSITIONS x EOSE IP PORTFOLIO x 14-GOAT LEGAL VERDICT

γ₁ = 14.134725141734693 · DCJ-102 + DCJ-103 P0 CRITICAL · AMANI GC EXECUTIVE AUTHORIZATION · FILE ORDER MATTERS

POSITIONS MAPPED

EOSE MOATs

DCJs FILED

P0 CRITICAL

CRITICAL OVERLAP

INTU — file first!

FLOOR LOCK ENTRY

MSFT·ASML·UNP

MODEL COMPANIES

QCOM · CRSP

MEEK FLIP x CLO IP FLEET x6 CLUSTER TD DASHBOARD CLO LIBRARY TRIAL HELIX

PRIORITY FILING MATRIX — ACTION REQUIRED

P0 THIS WEEK

DCJ-102 — MEFINE Debt Helix WPA

INTU at x28 floor: stock proves the IP thesis. Critical commercial overlap. File before Intuit next product launch.

P0 THIS WEEK

DCJ-103 — Helix Coaster Full Universe

7 simultaneous floor proof points: MSFT, ASML, UNP, QCOM, GOOGL, TSLA. Evidence is overwhelming. File now.

P0 THIS WEEK

DCJ-046 — γ₁ Anchor Canon (parent)

All other DCJs depend on this. Must be on file before any commercial exposure.

P1 30 DAYS

PEMCLAU GraphRAG Provisional

GOOGL DeepMind is the most dangerous IP competitor. 2-hop graph reasoning is the key claim to secure.

P1 30 DAYS

DCJ-036 — FC Chain (overdue from Day 81)

Fermentation Chamber chain is core architecture. Still marked overdue. File now.

P2 60 DAYS

DCJ-052 — WLD/Endocannabinoid analogy

Powerful narrative. Needs precise claim construction with counsel before filing.

EVIDENCE NOW

Floor Timestamp Archive

Every γ₁ floor hit is DCJ-103 court evidence. MSFT×30, ASML×103, UNP×19, QCOM×11, GOOGL×11 — timestamp daily.

STUDY

QCOM Royalty Architecture

Royalty-first model on every device sold = the MEFINE licensing blueprint. Analyze before first deal.

STUDY

CRISPR/Casgevy Licensing Model

License foundation IP, let others build applications. This is the MEFINE commercial path.

MEEK FLIP x CLO BRIDGE — 11 POSITIONS WITH LEGAL ANALYSIS

sorted: critical overlap first · Harvey · Ruth · Cochran · Amani GC

INTU

Intuit · PLATFORM

$395.95 · x28 $395.77 +0.045%

HIGH FLIP

CRITICAL IP

Flip 0.780

MOAT-086 DCJ-102 DCJ-036

EOSE IP OVERLAP

CRITICAL OVERLAP. Intuit TurboTax+QuickBooks SMB financial data could evolve toward γ₁-based floor analytics — COMPETING CLAIMS territory.

HARVEY

Most commercially dangerous intersection. Intuit Connect+AI bookkeeping could claim exactly what DCJ-102 describes. File BEFORE their next product.

RUTH

Need careful claim construction: γ₁ constant is the differentiator from Intuit rule-based thresholds. Be precise.

COCHRAN

If Intuit patents a debt floor concept after our provisional — they infringed. But we MUST file first. This is why P0 means this WEEK.

AMANI GC

HIGHEST PRIORITY CONFLICT. DCJ-102 + DCJ-036 must be provisionally filed before Intuit next product launch. Buy INTU after filing, not before.

MEEK FLIP x CLO VERDICT

FILE DCJ-102 PROVISIONAL FIRST. Then BUY INTU. Position profits from same thesis IP protects. Do not reverse order.

GOOGL

Alphabet/Waymo · AV/TECH

$155.22 · x11 $155.48 -0.168%

WATCH

SIGNIFICANT IP

Flip 0.550

MOAT-084 DCJ-101 DCJ-103

EOSE IP OVERLAP

SIGNIFICANT. DeepMind vs PEMCLAU. Intent sovereignty vs ad targeting.

HARVEY

File PEMCLAU before Google files any 2-hop graph claim.

RUTH

DCJ-031 intent protection is a direct legal counter to Google model.

COCHRAN

Git timestamps are your defense. Preserve them.

AMANI GC

Monitor Google IP quarterly.

MEEK FLIP x CLO VERDICT

BUY GOOGL at floor. File PEMCLAU within 60 days.

NVDA

NVIDIA · AI/SEMI

$208.27 · x15 $212.02 -1.769%

MONITOR

WATCH IP

Flip 0.350

MOAT-086 DCJ-103 MOAT-087

EOSE IP OVERLAP

CUDA ecosystem is infrastructure PEMCLAU runs ON. EOSE is customer/partner. But NVIDIA NIM microservices could eventually overlap MEFINE analytics.

HARVEY

PEMCLAU runs on NVIDIA hardware. If NVIDIA ships AI analytics, MEFINE γ₁ spine is the differentiator CUDA cannot replicate.

RUTH

CUDA software platform IP vs MEFINE mathematical analytics IP — distinguishable. But watch NIM and Morpheus products.

COCHRAN

DCJ-103 prior art protects γ₁-based analytics from any NVIDIA attempt to patent similar floor-proximity signals.

AMANI GC

Priority: Establish NVIDIA as EOSE infrastructure partner before any competitive NIM product launch.

MEEK FLIP x CLO VERDICT

WATCH NVDA for $212.02 floor reclaim. That is your DCJ-103 evidence timestamp AND your entry signal.

MSFT

Microsoft · PLATFORM

$424.62 · x30 $424.04 +0.136%

FLOOR LOCK

ADJACENT IP

Flip 0.950

DCJ-102 DCJ-103 MOAT-086 MOAT-087

EOSE IP OVERLAP

Debt Helix competes with any Azure AI financial analytics product. γ₁ spine is prior art MSFT cannot acquire.

HARVEY

DCJ-102 provisional blocks MSFT from patenting γ₁-based financial floors. File NOW before Build 2026.

RUTH

Application of γ₁ as financial spine with WPA architecture IS patentable as method claim.

COCHRAN

If MSFT ships floor-proximity trading signal, DCJ-103 diamond cluster prior art puts them in infringement.

AMANI GC

P0: Provisional within 30 days. MSFT at γ₁×30 = their stock proving our math. File before Build 2026.

MEEK FLIP x CLO VERDICT

BUY MSFT + FILE DCJ-102/103 SIMULTANEOUSLY. Position validates the IP. IP protects the thesis.

MRNA

Moderna · BIOTECH

$30.83 · x2 $28.27 +9.058%

MONITOR

ADJACENT IP

Flip 0.150

DCJ-052 MOAT-085

EOSE IP OVERLAP

mRNA biological error correction vs EOSE computational error correction. DCJ-052 identifies the homology. Potential cross-licensing narrative.

HARVEY

DCJ-052 endocannabinoid-WLD homology = unique framing no pharma company owns. Creates bridge between biotech IP and AI IP.

RUTH

DCJ-052 is architectural IP, not pharmaceutical. Be precise — NOT claiming pharmaceutical applications.

COCHRAN

CB1 retrograde inhibition → BRIGADE confidence restoration analogy needs cleaner scientific citation chain before filing.

AMANI GC

Proceed cautiously. Powerful narrative but must NOT imply pharmaceutical claims. Have counsel review before any filing.

MEEK FLIP x CLO VERDICT

WATCH MRNA at ×2=$28.27. Refine DCJ-052 language with patent counsel review.

ASML

ASML · AI/SEMI

$1457.70 · x103 $1455.88 +0.125%

FLOOR LOCK

NONE IP

Flip 0.850

MOAT-083 DCJ-046

EOSE IP OVERLAP

Physical EUV monopoly + mathematical resonance IP. Non-competing. ASML is a pure floor play and potential MEFINE licensing customer.

HARVEY

ASML at γ₁×103 = public proof of mathematical framework. Use as evidence in every IP licensing pitch.

RUTH

Zero IP overlap. ASML physical EUV has no conflict with EOSE mathematical IP.

COCHRAN

γ₁×103 hit = single best public proof point for DCJ-103 claims. Screenshot and timestamp — court exhibit.

AMANI GC

No filing urgency re ASML. Document ×103 floor hit as DCJ-103 evidence. Timestamp: 2026-04-24.

MEEK FLIP x CLO VERDICT

BUY ASML for the position. Document floor hit for DCJ-103 evidence record.

UNP

Union Pacific · INFRA

$268.70 · x19 $268.56 +0.052%

FLOOR LOCK

NONE IP

Flip 0.850

MOAT-082 DCJ-100

EOSE IP OVERLAP

Physical rail corridors vs digital sovereign pipeline. DCJ-100 Pipeline Racetrack = digital equivalent of UNP physical moat.

HARVEY

UNP = physical world proof that irreplaceable infrastructure commands sovereign pricing. Use as pitch deck comp.

RUTH

Physical rail and digital pipeline legally distinct. No IP conflict. UNP is market comp, not competitor.

COCHRAN

γ₁×19 on UNP validates DCJ-103 in physical infrastructure sector — strongest claim class for examiners.

AMANI GC

No conflict. Document as DCJ-103 multi-sector evidence.

MEEK FLIP x CLO VERDICT

BUY UNP. Add to DCJ-103 evidence dossier as infrastructure sector validation.

QCOM

Qualcomm · AI/SEMI

$154.08 · x11 $155.48 -0.902%

WATCH

NONE IP

Flip 0.580

DCJ-103 MOAT-083 DCJ-046

EOSE IP OVERLAP

QCOM royalty-first model = exact licensing blueprint for MEFINE. Adjacent, not competing. γ₁ analytics could license to chipset makers.

HARVEY

QCOM approaching ×11 from below = cleanest entry signal. QCOM royalty-first model is MEFINE licensing template.

RUTH

No IP conflict. QCOM wireless IP and EOSE mathematical finance IP are in separate claim spaces completely.

COCHRAN

QCOM at ×11 floor = DCJ-103 semiconductor sector validation. Add to evidence.

AMANI GC

Model company for EOSE licensing. Study royalty architecture. No conflict.

MEEK FLIP x CLO VERDICT

BUY QCOM approaching floor. Study their royalty model for MEFINE licensing blueprint.

TSLA

Tesla · AV/ENERGY

$241.37 · x17 $240.29 +0.449%

APPROACH

NONE IP

Flip 0.450

DCJ-102 MOAT-086 DCJ-103

EOSE IP OVERLAP

Tesla physical AI IP (battery, neural net). EOSE mathematical AI IP. Non-competing in patent space.

HARVEY

Tesla proves companies with algorithmic moats command premium valuations. Cite Tesla battery learning curve as comp for MEFINE γ₁ curve.

RUTH

No IP conflict. Tesla IP is in physical systems. EOSE IP is in mathematical frameworks.

COCHRAN

γ₁×17 on TSLA = another DCJ-103 multi-sector validation. Document.

AMANI GC

No conflict. Use TSLA as narrative comp for IP-anchored valuation story.

MEEK FLIP x CLO VERDICT

BUY TSLA at ×17. Add to DCJ-103 evidence. Use as IP valuation comp.

AMD

AMD · AI/SEMI

$100.02 · x7 $98.94 +1.088%

MONITOR

NONE IP

Flip 0.300

DCJ-103 MOAT-087

EOSE IP OVERLAP

AMD ROCm = open CUDA competitor. EOSE fleet uses NVIDIA now. MI300X = potential PEMCLAU compute upgrade. Non-competing IP.

HARVEY

AMD at γ₁×7 = clean entry. AMD ROCm success means cheaper PEMCLAU compute. Bullish for EOSE infrastructure cost.

RUTH

No IP conflict.

COCHRAN

γ₁×7 = DCJ-103 semiconductor sector validation. Add to evidence.

AMANI GC

No conflict. Consider AMD hardware for PEMCLAU cost optimization.

MEEK FLIP x CLO VERDICT

BUY AMD at ×7. Add to DCJ-103 evidence. Monitor ROCm for PEMCLAU migration opportunity.

CRSP

CRISPR Therapeutics · BIOTECH

$36.75 · x3 $42.40 -13.334%

FAR BELOW

NONE IP

Flip 0.050

DCJ-052 MOAT-085

EOSE IP OVERLAP

CRISPR precision error correction in biology vs MEMECHET precision error detection in math/computation. 287 named sorries = structural homolog of CRISPR target-and-correct.

HARVEY

CRISPR business model: license the platform, let others build therapies. This is EXACTLY the MEFINE licensing path.

RUTH

No IP conflict. Biological and computational error correction in separate patent classes completely.

COCHRAN

Sorry-chain framework (287 named sorries, Lean4 formal verification) = court-quality proof. Same documentation standard as Broad Institute CRISPR edits.

AMANI GC

CRISPR licensing model study: license foundation IP, let others build applications. This is the MEFINE commercial path.

MEEK FLIP x CLO VERDICT

WATCH CRSP at $42.40 floor. Use CRISPR licensing model as MEFINE commercial blueprint.